Randomized Phase II Study of Ficlatuzumab (formerly AV-299), an Anti-Hepatocyte Growth Factor (HGF) Monoclonal Antibody (MAb) in Combination with Gefitinib (G) in Asian Patients (pts) with NSCLC
Invited conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者MOK Shu Kam Tony, TAN E, PARK K, JAC J, HAN M, PAYUMO Fc, CREDI M, MCKEE K, COTREAU Mm, BHARGAVA P, SLICHENMYER W
會議名稱2011 ASCO Annual Meeting Proceedings
會議國家/地區美國
會議論文集題名2011 ASCO Annual Meeting Proceedings
詳細描述organized by American Society of Clinical Oncology,
出版年份2011
月份6
出版地United States of America
頁次35
語言英式英語
關鍵詞Ficlatuzumab; HGF; NSCLC

上次更新時間 2018-18-01 於 20:08